https://stanfordhealthcare.org/publications/928/928279.html
928279 | Stanford Health Care
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignanci
stanfordhealthcare